Age and Bone Marrow Cellularity are Associated with Response to Eltrombopag in Japanese Adult Immune Thrombocytopenia Patients: A Retrospective Single-Center Study

摘要

In the present retrospective single-center study, we examined the efficacy and safety of eltrombopag, a thrombopoietin (TPO) -receptor agonist (TPO-RA) ， and found clinical factors associated with its efficacy in Japanese patients with chronic immune thrombocytopenia (ITP).According to the definition of a response, which is to attain a platelet count of more than 50,000/muL at least once during eltrombopag treatment, 42 enrolled patients were divided into two groups: responders (29 patients, 69%) and non-responders (13 patients, 31%). In analyses of the clinical and laboratory data of these two groups, we extracted two factors that are significantly associated with a better response to eltrombopag, which have not been recognized previously, namely, (Dan older age of patients at eltrombopag initiation(> 70 years old) ， and (2) normal or decreased cellularity of iliac bone marrow (BM) biopsy at diagnosis.